Niraparib
About
Therapy type: Targeted therapy
Therapy strategy: PARP inhibition
Mappings
NCI Thesaurus: Niraparib (ncit:C80059)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | BRCA1 oncogenic variants | Prostate Adenocarcinoma | Abiraterone acetate, Niraparib, Prednisone | |
| Sensitivity (+) | BRCA1 pathogenic variants | Prostate Adenocarcinoma | Abiraterone acetate, Niraparib, Prednisone | |
| Sensitivity (+) | BRCA2 oncogenic variants | Prostate Adenocarcinoma | Abiraterone acetate, Niraparib, Prednisone | |
| Sensitivity (+) | BRCA2 pathogenic variants | Prostate Adenocarcinoma | Abiraterone acetate, Niraparib, Prednisone | |
| Sensitivity (+) | BRCA1 pathogenic variants | Ovarian Epithelial Tumor | Niraparib | |
| Sensitivity (+) | BRCA2 pathogenic variants | Ovarian Epithelial Tumor | Niraparib | |
| Sensitivity (+) | BRCA1 pathogenic variants | High-Grade Serous Fallopian Tube Cancer | Niraparib | |
| Sensitivity (+) | BRCA2 pathogenic variants | High-Grade Serous Fallopian Tube Cancer | Niraparib | |
| Sensitivity (+) | BRCA1 pathogenic variants | Peritoneal Serous Carcinoma | Niraparib | |
| Sensitivity (+) | BRCA2 pathogenic variants | Peritoneal Serous Carcinoma | Niraparib |